---
title: "Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286675157.md"
description: "Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News"
datetime: "2026-05-17T06:15:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286675157.md)
  - [en](https://longbridge.com/en/news/286675157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286675157.md)
---

# Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News

### Related Stocks

- [NBTX.US](https://longbridge.com/en/quote/NBTX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer](https://longbridge.com/en/news/286776980.md)
- [Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study  | NBTX Stock News](https://longbridge.com/en/news/285126081.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)